The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada.

Sunjeev UthayakumarMina TadrousSimone N VigodSophie A KitchenTara Gomes

Published in: Depression and anxiety (2021)

Despite the increased reporting of depressive and anxious symptoms during the COVID-19 pandemic, there have been no changes in the dispensing trends of medications used to treat these disorders. As the pandemic continues to evolve, future research is needed to monitor the prevalence of depression and anxiety, and associated medication use, in the Canadian population.

Keyphrases

coronavirus disease
sars cov
major depressive disorder
bipolar disorder
risk factors
current status
respiratory syndrome coronavirus
adverse drug
stress induced
sleep quality
emergency department